Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryo Ishida

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Science Advances|March 30, 2022
Structure-guided design enables development of a hyperpolarized molecular probe for the detection of aminopeptidase N activity in vivoYutaro Saito, Hiroyuki Yatabe, Iori Tamura, et al.
The Prostate|December 21, 2019
Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patientsMasashi Kato, Akihiro Hirakawa, Yumiko Kobayashi, et al.
PNAS Nexus|April 24, 2023
Mitoribosome sensitivity to HSP70 inhibition uncovers metabolic liabilities of castration-resistant prostate cancerFrank J Echtenkamp, Ryo Ishida, Genesis M Rivera-Marquez, et al.
The Prostate|April 27, 2019
The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performanceMasashi Kato, Akihiro Hirakawa, Yumiko Kobayashi, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 6, 2018
Integrating tertiary Gleason pattern 5 into the ISUP grading system improves prediction of biochemical recurrence in radical prostatectomy patientsMasashi Kato, Akihiro Hirakawa, Yumiko Kobayashi, et al.
Scientific Reports|July 27, 2025
Low levels of tumor suppressor miR-3619 in plasma contribute to malignant outcomes and a target for nucleic acid therapy in esophageal cancerHiroshi Arakawa, Shuhei Komatsu, Takuma Kishimoto, et al.
Japanese Journal of Clinical Oncology|October 18, 2008
Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology GroupNoriyuki Katsumata, Yasuhiro Fujiwara, Toshiharu Kamura, et al.
British Journal of Cancer|December 26, 2023
Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancerHajime Kamiya, Shuhei Komatsu, Yusuke Takashima, et al.
Scientific Reports|December 8, 2025
Overexpression of JMJD6 drives immune evasion via the BRD4-IRF1-PD-L1 axis and promotes malignancy in gastric cancerRyo Ishida, Shuhei Komatsu, Hajime Kamiya, et al.
American Journal of Cancer Research|February 14, 2025
Overexpression of SHANK2 contributes malignant outcomes as a Hippo pathway regulator in gastric cancerHiroshi Arakawa, Shuhei Komatsu, Jun Kiuchi, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Science Advances|March 30, 2022
Structure-guided design enables development of a hyperpolarized molecular probe for the detection of aminopeptidase N activity in vivoYutaro Saito, Hiroyuki Yatabe, Iori Tamura, et al.
The Prostate|December 21, 2019
Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patientsMasashi Kato, Akihiro Hirakawa, Yumiko Kobayashi, et al.
PNAS Nexus|April 24, 2023
Mitoribosome sensitivity to HSP70 inhibition uncovers metabolic liabilities of castration-resistant prostate cancerFrank J Echtenkamp, Ryo Ishida, Genesis M Rivera-Marquez, et al.
The Prostate|April 27, 2019
The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performanceMasashi Kato, Akihiro Hirakawa, Yumiko Kobayashi, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 6, 2018
Integrating tertiary Gleason pattern 5 into the ISUP grading system improves prediction of biochemical recurrence in radical prostatectomy patientsMasashi Kato, Akihiro Hirakawa, Yumiko Kobayashi, et al.
Scientific Reports|July 27, 2025
Low levels of tumor suppressor miR-3619 in plasma contribute to malignant outcomes and a target for nucleic acid therapy in esophageal cancerHiroshi Arakawa, Shuhei Komatsu, Takuma Kishimoto, et al.
Japanese Journal of Clinical Oncology|October 18, 2008
Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology GroupNoriyuki Katsumata, Yasuhiro Fujiwara, Toshiharu Kamura, et al.
British Journal of Cancer|December 26, 2023
Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancerHajime Kamiya, Shuhei Komatsu, Yusuke Takashima, et al.
Scientific Reports|December 8, 2025
Overexpression of JMJD6 drives immune evasion via the BRD4-IRF1-PD-L1 axis and promotes malignancy in gastric cancerRyo Ishida, Shuhei Komatsu, Hajime Kamiya, et al.
American Journal of Cancer Research|February 14, 2025
Overexpression of SHANK2 contributes malignant outcomes as a Hippo pathway regulator in gastric cancerHiroshi Arakawa, Shuhei Komatsu, Jun Kiuchi, et al.
Pageof 9